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The following review summarizes two important articles on 
heart failure and cardiomyopathy that were published in the 
American Journal of  Cardiology two decades apart. Both 
articles are extraordinary in their link to the more modern 
era of cardiology, and specifically to the area of  heart failure. 
Heart Failure from the Point of 
View of Quantitative Anatomy 
by A. J. Linzbach (1) 
SUMMARY 
1. All normal human hearts have essentially the same number 
of myocardial fibers and myocardial nuclei. During physiologic 
growth the number of myocardial fibers remains constant; the 
fibers enlarge, but their length-to-width ratio remains constant 
(harmonic growth). The number of capillaries increases with 
growth, with one capillary per four fibers in the infant and one 
capillary per fiber in the adult. Howevel, the width of the spaces 
of the capillary net is essentially the same for all age groups. The 
number of fibers and nuclei is roughly the same for the right 
ventricle as the left; the left ventricle is heavier than the right 
because its fibers are thicker. There are fewer layers of ibers in the 
right ventricle than in the l•. It follows from this that the inner 
smface area of the right ventricle must be greater than for the left. 
2. The average weight of the normal heart in man is about 
300 gm. Through athletic exertion it can attain a weight of 
500 gm. This increase is due to an extension of physiologic 
growth, with the fibers increasing in length and width but not 
increasing in number. The growth results in a larger than 
normal mobilizable blood volume. 
3. As a result of pathologic demands for increased heart work 
as, for example, in hypertension, the "critical" heart weight of 
500 gm. is exceeded. Increases in heart weight above the 
"critical" level are due to increase in the number of fibers with 
little further thickening. There is also an increase in capillaries, 
with the ratio of one capillary per fiber maintained. The 
coronary insufficiency than occurs with advanced hypertrophy is
not principally due to a failure of capillary supply but to the fact 
that with hypertrophy the growth of the coronary arteries and 
coronary ostia is retarded and atherosderotic lesions of the 
coronary system become more frequent. 
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4. As a result of the coronary insud~ciency a dilatation takes 
place. However, the Z-band to Z-band distance (i.e., the length 
of sarcomeres) ofmyocardial fibers in dilated hearts is the same 
as for normal hearts. In addition to longitudinal growth of the 
muscle fibers in dilatation there are also structural alterations in 
the myocardium with ream'angements of the architectural rela- 
tionship among the muscle fibers. Therefore, dilatation as 
encountered in man is not characterized by overstretched fibers. 
50th Anniversary Historical Article 
INTRODUCTION 
In this edition of the Journal, we release the second in a series 
of reviews of influential articles that have been previously 
published in ACC journals, including the American Jomwal of 
Cardiology (from 1958 to 1982), andJACC (from 1983 to the 
present). The publication of these articles is only one aspect of 
the ACC's 50th anniversary commemoration, which highlights 
50 years of leadership in cardiovascular care and education. The 
articles are intended to encourage r flection on the remarkable 
progress made in cardiovascular medicine over time, as well as 
to acknowledge the amazing prescience of some early investi- 
gators in anticipating and, in many cases, later guiding devel- 
opments in their field. 
The working group responsible for selecting these articles and 
asking reviewers to write editorials solicited suggestions from 
the ACC's clinical committees and individual members. 
The group achieved consensus fairly easily, including whom the 
group should ask to prepare the accompanying editorials. We 
initially drew up a list of 14 general areas to cover in this series, 
but later found that there are several major areas of modern 
cardiology, prominently molecular cardiology in which the truly 
landmark articles have, alas, not yet been published in JACC. 
Therefore, the working group decided not to categorize by 
subject, but instead, to concentrate on the most important 
articles. 
The working group, a task force of the Subcommittee for the 
Commemoration f the ACC 50th Anniversary, owes a great 
deal to Ms. May A. Roustom and the efficient and tireless taff 
at Heart House for facilitating this project. We also wish to 
thank all who suggested articles and, most important, the 
authors who prepared reviews for their willingness to contribute 
their time and wisdom. 
Influential Articles in JACC Working Group 
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This is true of dilatation whether due to coronary sclerosis, 
myocarditis or excessive hypertrophy. It is called "structural 
dilatation" as opposed to the '~nctional dilatation" of the 
acutely overloaded heart. There is an increased residual ventric- 
,lar volume in the dilated heart, but it is not mobilizable. 
5. Stm~ctural di atation is the morphologic substrate of the 
decompensated h art. The cross ection area of muscle capable of 
contracting istoo small for the ino'eased volume of the ventricle. 
Cardiac insuAffciency results, notjqom overstretching of the fibers 
or inadequate oxygen consumption per fiber length in the 
Starling sense, but for strictly mechanical reasons. The unit 
muscle weight may produce a normal amount of energy liberated 
on contraction but it is no longer adequate to expel a normal 
stroke volume )5-om a ventricle of these dimensions. In other 
words, the essence of myocardial failure is the discrepancy 
/~etween the amount of energy necessary toexpel a stroke volume 
,rod the anmunt of energy available. In these studies it has been 
.~hown that in most clinical cardiac disorders with heart failure 
the discrepancy an be adduced from changes in the quantitative 
morphology of the heart. 
Originally published in The American Journal of Cardiology, March 1960 
Review 
It is remarkable that for more than 100 years dispute has 
persisted and continues to occupy the editorial pages of 
scholarly journals regarding the fundamental mechanism of 
heart failure. Linzbach points out in his classic 1960 article 
"Heart failure from the point of view of quantitative 
anatomy" that at the turn of the century clinicians champi- 
oned a morphologic point of view regarding hypertrophy 
and heart failure, whereas pathologists defended a primary 
functional abnormality (1). Although a functional basis for 
heart failure has gradually won the hearts and minds of 
investigators in recent times, there is now a growing 
recognition that left ventricular remodeling and structural 
problems related to remodeling may be the core lesion of 
chronic heart failure, with functional abnormalities being 
perhaps more of a secondary phenomenon (2). 
It was Linzbach's belief that the pathophysiologic abnor- 
malities of the heart, including heart failure, could only be 
understood when quantitative structural relations of this 
organ were known. Measurable changes in the size and 
shape of the diseased heart were an essential requirement. In 
Linzbach's 1960 paper he points out that in both normal 
and abnormal hearts, the average distance between Z bands, 
which is the length of the sarcomeres, was in all cases 1.4/.~. 
This important finding, that the length of the sarcomeres is 
not altered by hypertrophy or pathologic dilatation, was a 
landmark observation. He also pointed out that the sarco- 
mere length was virtually the same for a wide variety of 
mammals, uggesting that this feature was highly conserved 
throughout evolution. Experiments conducted by Linzbach 
and his group led them to estimate that normal ventricular 
filling involved a change of sarcomere l ngth from 1.4-1.5 
/x to 2 ~. He pointed out that the maximum sarcomere 
lengthening still compatible with normal heart function is a 
tittle beyond 2 /z. This extraordinarily important observa- 
tion meant hat stretching of the muscle fibers to adapt o 
heart function is highly limited. 
Linzbach's laboratory had previously demonstrated that 
all normal human hearts have essentially the same number 
of myocytes and nuclei (3). Even though the right ventricle 
is about half as heavy as the left ventricle, it has essentially 
the same number of cells or myocytes. The cells of the right 
ventricle were demonstrated by him and others to be smaller 
than those of the left ventricle, and were arranged somewhat 
differently. The paper goes on to demonstrate hat during 
normal postnatal growth of the heart, the cardiac myocytes 
become wider and longer but maintain a fixed length to 
width ratio. This concept is most important in the context 
of today's understanding regarding morphometric changes 
that occur in heart failure. Gerdes and colleagues have 
demonstrated that an alteration of the length-width ratio is 
one of the most consistent changes that occurs during left 
ventricular remodeling (4). The largest myocytes observed 
by Linzbach and colleagues were in patients with heart 
failure, and this has been confirmed by Gerdes and col- 
leagues using more modern techniques of cell isolation (5). 
Most importantly, Linzbach points out that as physio- 
logic or pathologic hypertrophy occurs, the increase in the 
weight of the heart is not due to an increase in the number 
of cardiac myocytes, but is rather due to the cardiac 
myocytes becoming thicker and longer. There is basically an 
extension of the physiologic growth process of each cell. 
Linzbach made the distinction between physiologic hyper- 
trophy and pathologic hypertrophy based on the weight of 
the heart. He considered 500 grams to be the critical heart 
weight beyond which pathologic hypertrophy was occur- 
ring. In the paper he points out that a left ventricular weight 
of 200 grams or more is also consistent with pathologic 
hypertrophy. Without the advantage of modern cell isola- 
tion techniques, Linzbach conceded that there may be an 
increase in the number of cardiac myocytes and cardiac 
myocyte nuclei in concentric pressure hypertrophy. Today 
we recognize that indeed there may be some post-neonatal 
myocardial cell hyperplasia, nd it may be increased in the 
failing heart (6). In general, most experts continue to believe 
that cardiac myocytes, being highly differentiated cells, 
uncommonly enter into cell cycle. However, they clearly do 
increase in size, although this is normally not accompanied 
by ploidy or an increase in the number of nuclei. Despite 
nearly 40 years ince the publication of the Linzbach paper, 
this field remains an area of disputatious but intense study. 
In the 1960 paper Linzbach goes on to describe the 
anatomic basis of left ventricular dilatation. He observes 
that cardiac myocytes may become stretched in diastole, but 
again finds that the Z band to Z band distance appears fixed 
at 1.4/z, which is the same as in the normal and undilated 
hypertrophied heart. He goes on to state that the dilation of 
these hearts must then involve plastic structural changes 
within the myocardium, probably due to elongation of 
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individual cardiac cells. He speculates that focal hypofic 
necrosis commonly occurs during dilation, causing over 
stretching during isometric ontraction. He recognizes that 
cardiac dilation can occur without hypertrophy, and is seen 
in various types of cardiomyopathy including diphtheritic 
myocarditis and chronic coronary atherosclerosis. Impor- 
tantly, Linzbach points out that structural dilatation of the 
heart is a hallmark of decompensated heart failure. This 
principle still holds today, and is the basis for the develop- 
ment of innovative anti-remodeling drugs, such as matrix 
metalloproteinase inhibitors. He makes the interesting 
point that heart failure results not from inadequate oxygen 
consumption per cardiac myocyte, but is a consequence 
strictly of mechanical inefficiency. He hypothesizes that 
each "unit muscle weight" in heart failure likely produces a
normal amount of energy during contraction, but that this 
amount of energy is no longer adequate to expel a normal 
stroke volume from a ventricle with markedly enlarged 
dimensions. The large, dilated heart structurally obfigates a
low ejection fraction. This concept was revisited in a recent 
editorial (7). 
The Natural History of Idiopathic 
Dilated Cardiomyopathy 
by Fuster V, Gersh BJ, Giuliani ER, Tajik AJ, 
Brandenburg RO, Frye RL (8) 
AB$1~ 
Between 1960 and 1973, a total of lO4 patients at the Mayo 
Clinic had a diagnosis of idiopathic dilated cardiomyopathy on
the basis of clinical and angiographic riteria; these patients 
were followed up for 6 to 20 years. Twenty-one percent of the 
patients had a history of excessive consumption of alcohol, 20 
percent had had a severe influenza-like syndrome within 60 
days before the appearance of cardiac manifestations and 8 
percent had had rheumatic fiver without involvement ofcardiac 
valves everal years before; thus, possible tiologic risk factors of 
infictious-immunologic type may be important. Eighty patients 
(77percent) had an acccelerated course to death, with two thirds 
of the deaths occurring within the first 2 years. Twenty-four 
patients (23 percent) survived, and 18 of them had clinical 
improvement and a normal or reduced heart size. Univariate 
analysis at the time of diagnosis revealed three factors that were 
highly predictive (p less than 0.01) of the clinical course: age, 
cardiothoracic ratio on chest roentgenography and cardiac index. 
Systemic emboli occurred in 18 percent of the patients who did 
not receive anticoagulant therapy and in none of those who did; 
thus, anticoagulant agents hould probably be prescribed unless 
their use is contraindicated. 
Originally published in The American Journal of Cardiology, March 1981 
Revie~ 
The paper by Fuster and colleagues on the natural history of 
idiopathic dilated cardiomyopathy remains a time-honored 
classic (8). The study was basically a carefully performed 
retrospective analysis of 104 patients studied at the Mayo 
Clinic between 1960 and 1973 with a diagnosis of idio- 
pathic dilated cardiomyopathy. The diagnosis was estab- 
fished on the basis of rigorous clinical and angiographic 
criteria. Follow-up varied from six to twenty years. Al- 
though it is a retrospective study with inherent selection 
bias, it provides some of the most accurate information 
derived from a systematic set of observations at a single 
institution on this important diagnosis. In essence, the 
authors believed it was the study of the natural history of 
idiopathic dilated cardiomyopathy and therefore unique. ALl 
of the patients underwent cardiac catheterization at base- 
line, and the duration of follow-up was the longest reported 
to date. It is a classic example of how a carefully done 
descriptive study (i.e., non-hypothesis driven) can still have 
an enormous impact on a field of study. 
The authors were clearly ahead of their time in suggesting 
that early identification of the syndrome prior to the 
development ofventricular dilation, presumably by echocar- 
diography, could enable earlier and possibly more successful 
therapeutic intervention. This speculation was later realized 
during the organization and implementation of the SOLVE) 
(Studies Of Left Ventricular Dysfunction) prevention trial. We 
now know that early introduction of angiotensin converting 
enzyme inhihitors forestalls the onset of heart failure and 
markedly reduces the need for hospitalization (9). 
The important issue of systemic embolism in dilated 
cardiomyopathy was addressed by Fuster et al. (8). They 
noted that over half of the emboli occurred within the first 
year of diagnosis, and suggested that such patients might 
benefit from administration of oral anticoagulant agents. 
They firmly state in the paper that their current policy is to 
prescribe long term anticoagulant therapy in all patients 
with idiopathic dilated cardiomyopathy unless there is a 
specific contraindication. The issue of whether or not to 
anticoagulate such patients still has not been completely 
resolved, with strong feelings both for (10) and against (11). 
Uncontrolled ata would suggest that some anticoagulation 
may be useful for selected patients with heart failure (12). A 
large randomized controlled trial has recently been planned 
and will likely be launched in the near future to better 
resolve this important clinical question. 
The Fuster paper points out that about wo-thirds of the 
patients die in the first two years after diagnosis, demon- 
strafing an accelerated course to death. On the other hand, 
the remaining patients demonstrated subjective improve- 
ment, and many went on to stabilize with even some 
diminishment in heart size. The authors recognized that the 
more severe the clinical and hemodynamic manifestations at
the time of diagnosis, the worse the long term prognosis. 
Since then many investigators have demonstrated that high 
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filling pressures and a low cardiac index are associated with 
a very poor prognosis. The Mayo group recognized that 
21% of the patients with idiopathic dilated cardiomyopathy 
were identified as having excessive alcohol consumption 
according to standard criteria. They went on to reiterate that 
alcohol may be deleterious in any patient with cardiomyop- 
athy, and recommend complete abstinence from alcohol. 
Only three of the patients had peri-partum cardiomyopathy, 
,rod the authors believed that a family history of  idiopathic 
dilated cardiomyopathy was rare, occurring in only 2 of 104 
patients. More current information would suggest that 
f:amilial cardiomyopathy may be more common (13,14), but 
this is clearly an area that needs additional study. 
The Fuster paper ends by making suggestions for future 
investigators, including the need to make prospective and 
,ystematic observations in various populations at risk, the 
need for sequential biopsies to assess the histological and 
ultra-structural changes, and the necessity to develop sero- 
logic identification markers for possible infectious and 
.nmunologic processes. In fact, myocardial biopsy of pa- 
rLents with dilated cardiomyopathy is perhaps done less 
frequently today, in part because it has seemingly little 
Hnpact on the management of the syndrome. Specific 
histologic and ultra-structural changes as well as serological 
identification of infectious and immunologic processes have 
generally been lacking, although myocardial biopsy is still 
required for the diagnosis of inflammatory myocarditis and 
infiltrative cardiomyopathies. The paper remains a classic in 
that it accurately portrays the natural history of idiopathic 
dilated cardiomyopathy asviewed in 1981 in a manner that 
very much mirrors today's view of this common disorder. 
Although treatment has improved over the years, an under- 
,~tanding of the biologic underpinnings of the syndrome 
remain for future investigation. 
These two papers are extraordinary in their link to the 
more modern era of cardiology, and specifically to the area 
,,f heart failure. Both of them are well worth re-reading. 
What is striking is how the key observations were made, 
even though the techniques are somewhat dated by today's 
standards. Nevertheless, these two papers further emphasize 
that careful studies done in relatively small numbers of 
patients can lead to profound and lasting mechanistic enlight- 
enment, a feature usually missing fi'om today's mega trials. 
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